Ocugen Inc. (NASDAQ: OCGN) has been making headlines following a recent buy rating from Chardan Capital. The investment firm placed a buy rating on Ocugen, highlighting the company’s potential for growth within the biotechnology sector. In recent trading sessions, Ocugen’s stock witnessed a notable rise, outperforming the broader market trends. Specifically, the stock jumped by approximately 5.7% on Tuesday, reflecting investor optimism fueled by the supporting analysis from Chardan. Notably, this surge was observed amidst mixed market conditions, where many biotechnology companies were struggling. Chardan’s analyst offered a bullish perspective, stating, “Ocugen’s innovative approaches in gene therapies position them well for future success, especially considering their pipeline which focuses on ophthalmic diseases.” As of the close of trading on Tuesday, Ocugen’s stock price settled at $2.18 per share. The stock’s upward trajectory has garnered attention from retail investors, suggesting a growing interest in the company’s developments. This increase may provide Ocugen with the momentum needed as it continues to advance its research and clinical trials.
Ocugen Inc. Receives Buy Rating from Chardan Capital Amidst Stock Surge
